CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX)

Q1 2018 13F Holders as of 3/31/2018

Type / Class
Equity / COMMON STOCK
Shares outstanding
123M
Number of holders
96
Total 13F shares, excl. options
54.7M
Shares change
-1.94M
Total reported value, excl. options
$131M
Value change
-$11.1M
Put/Call ratio
1.1
Number of buys
55
Number of sells
-44
Price
$2.39

Significant Holders of CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) as of Q1 2018

123 filings reported holding CPRX - CATALYST PHARMACEUTICALS, INC. - COMMON STOCK as of Q1 2018.
CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) has 96 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 54.7M shares of 123M outstanding shares and own 44.41% of the company stock.
Largest 10 shareholders include Broadfin Capital, LLC (6.81M shares), Consonance Capital Management LP (4.99M shares), BlackRock Inc. (4.7M shares), venBio Select Advisor LLC (4.69M shares), BAKER BROS. ADVISORS LP (4.38M shares), VANGUARD GROUP INC (3.98M shares), GREAT POINT PARTNERS LLC (2.7M shares), MANGROVE PARTNERS (1.51M shares), RENAISSANCE TECHNOLOGIES LLC (1.39M shares), and MILLENNIUM MANAGEMENT LLC (1.38M shares).
This table shows the top 96 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
Investor Option Weight % Change % Value $ * Price $ Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.